Xeris Biopharma (NASDAQ:XERS) Director Marla Persky Sells 15,500 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Marla Persky sold 15,500 shares of the business’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $5.90, for a total value of $91,450.00. Following the transaction, the director owned 126,500 shares of the company’s stock, valued at $746,350. This trade represents a 10.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Price Performance

Shares of NASDAQ:XERS traded up $0.03 during trading on Friday, reaching $6.18. The company had a trading volume of 1,028,207 shares, compared to its average volume of 1,829,779. The firm’s fifty day moving average is $6.08 and its 200 day moving average is $6.60. The firm has a market capitalization of $1.07 billion, a PE ratio of 103.00 and a beta of 0.78. Xeris Biopharma Holdings, Inc. has a twelve month low of $4.30 and a twelve month high of $10.08. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.01 EPS for the quarter. The business had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. On average, equities analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Kestra Advisory Services LLC purchased a new position in shares of Xeris Biopharma in the fourth quarter worth approximately $25,000. KBC Group NV acquired a new position in Xeris Biopharma in the 1st quarter worth approximately $27,000. AlphaQuest LLC acquired a new position in Xeris Biopharma in the 3rd quarter worth approximately $35,000. Caitong International Asset Management Co. Ltd grew its position in Xeris Biopharma by 9,276.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after purchasing an additional 7,421 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Xeris Biopharma by 29.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after purchasing an additional 1,820 shares during the period. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

XERS has been the subject of several research analyst reports. Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Xeris Biopharma in a report on Monday, March 2nd. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.80.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.